NextCell Pharma publish Interim Report 1 2024/2025

January 30, 2025

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2024 – November 30, 2024. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

First Quarter (2024-09-01 to 2024-11-30)

Operating income amounted to 2,864 (4,695) TSEK, of which Cellaviva contributed 2,828 (4,246) TSEK.
Net sales amounted to 2,828 (4,246) TSEK.
Profit/loss after financial items amounted to -8,042 (-9,796) TSEK.
Earnings per share* were -0.11 (-0.28) SEK.
Cash and cash equivalents amounted to 34,123 (40,428) TSEK.
Equity ratio** amounted to 86 (81) percent.

*Earnings per share: Net result for the period divided by the average number of shares. The average number of shares for the first quarter of 2024/2025: 73,091,327 (34,379,523) shares. The number of shares in NextCell as of 30 November 2024: 73,091,327 (34,379,523) shares.
**Equity ratio: Shareholders’ equity as a percentage of total assets.

Significant events and news during the first quarter

At the beginning of September, the Company presented new clinical long-term data at the International Society for Cell and Gene Therapy (ISCT) 2024 Regional Meeting. The results demonstrate the long-term safety and efficacy of the treatment in preserving endogenous insulin production, along with additional health benefits for patients with type 1 diabetes (T1D), such as lower BMI and blood pressure.
At the end of September, the Company announced that the first four children in the 7–11 age group had been treated in the latest phase of the ProTrans-Young study, with an additional four children screened and expected to begin treatment shortly. These developments mark a significant milestone in the study, which is progressing faster than anticipated.
In early October, the Company announced that ProTrans was highlighted as a promising treatment for type 1 diabetes in Dagens Medicin.
In early November, NextCell Pharma participated in BIO-Europe 2024, one of Europe’s most important partnering conferences in biotechnology and pharmaceutical development, which was attended by Sweden's Minister for Energy and Enterprise and Deputy Prime Minister, Ebba Busch.
At the end of November, QVance, a subsidiary of NextCell Pharma, announced two significant partnerships with bioMérieux Sweden and Royal International.
In late November, the Company announced that Eva Sjökvist Saers was elected as a new board member at the Annual General Meeting.

Significant events after the reporting period

In December, NextCell reported new results from the ProTrans-Repeat study. "The results from the ProTrans-Repeat study are very encouraging and show that repeated treatment can preserve and even improve insulin production over six years. This strengthens ProTrans' potential as a safe and effective treatment for modifying the progression of type 1 diabetes," commented Mathias Svahn, CEO.

This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on
30th January 2025, 08.30 CET.

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Patrik Fagerholm, CFO

Tel: 0+46 8-735 5595

E-mail: info@nextcellpharma.com

Website: www.nextcellpharma.com

LinkedIn: https://www.linkedin.com/company/15255207/

Twitter: https://twitter.com/NextCellPharma

For information about Cellaviva, please contact:

Sofie Falk Jansson, CEO

Tel: 08-735 2010

E-mail: info@cellaviva.se

Website: www.cellaviva.se

Facebook: https://www.facebook.com/cellavivasverige

Twitter: https://www.instagram.com/cellaviva/

Certified Adviser
FNCA Sweden AB is assigned as Certified Adviser

About NextCell Pharma AB

NextCell is a cell therapy company in Phase II trials with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a phase III trial. In addition to type 1 diabetes. NextCell owns Cellaviva AB, Scandinavia’s largest private stem cell bank licensed by the Swedish Health Authority (IVO) to preserve and store stem cells from umbilical cord blood and umbilical cord tissue for family use. NextCell also owns QVance which will offer quality control analytics for advanced therapy developers. Furthermore, NextCell owns 8.5% in FamicordTX, a CAR-T start-up in oncology.

Download attachment Read full press release on Cision (external link)

2017-10-17

NextCell Pharma's stem cell study in Type 1 Diabetes gets green light from the Medical Products Agency

NextCell Pharma AB ("NextCell") today announces that the Swedish Medical Products Agency has granted permission to conduct the clinical trial investigating the drug candidate ProTrans. For more information regarding the clinical trial, please see press release from 15th of September. This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the above contact person for publication on October 17th, 2017.

Read more Read more

2017-10-11

Family saving of stem cells at Underbara Barn held atStockholm International Fair and Congresses Centre,13-15 October, 2017

For the third consecutive year, Cellaviva will exhibit at the Underbara Barn Fair to meet and inform its (prospective) customers. The fair is targeted at future parents and those with young children. Representatives from the company will inform visitors about the family saving of stem cells from the umbilical cord. Cellaviva is Sweden's first and only biobank for family-saving of stem cells and is owned by the stem cell company NextCell Pharma AB (NEXTCL). The applications for stem cell therapy are rapidly growing in modern medicine. Cells from family members are preferred for the treatment

Read more Read more

2017-09-21

NextCell Pharma receives wholesale distribution authorisation

NextCell Pharma AB ("NextCell") today announces that the company has been granted license for wholesale of cell based investigational medicinal products. The company was inspected earlier this summer by the Swedish Medical Products Agency. The permission is required for NextCell to acquire, stock and distribute investigational drugs in the planned clinical trial of ProTrans™ for treatment of diabetes. CEO Mathias Svahn says “This license is a good next step towards the start of our first clinical trial with ProTrans™ for the treatment of patients with Type 1 diabetes”. About the clinical

Read more Read more

2017-09-15

Update on NextCell Pharma’s clinical trial application

NextCell Pharma AB (NEXTCL) today announced that the company has responded to the Medicinal Product Agency's request for completion regarding the application for clinical trial with ProTrans ™. The study is designed to evaluate safety and efficacy in the treatment of type 1 diabetes. NextCell’s application was registered with the Medical Products Agency on July 24th and request for supplementary information was received on September 5th. This has now been submitted within the deadline of September 14th. The study is divided into two parts: The first part is a three-step dose escalation

Read more Read more

2017-09-05

NextCell Pharma AB receives approval from Ethics Committee for Clinical Trial

NextCell Pharma AB (NEXTCL) announced today that the clinical trial application for ProTrans™ has been granted by the Ehtics Committee. ProTrans™ is a stem cell product developed with NextCell's Proprietary Selection Algorithm. The clinical trial is designed to evaluate the safety and efficacy of ProTrans™ for treatment of patients with type 1 diabetes. The study sponsor is NextCell and the principal investigator is Professor Per-Ola Carlsson, who works at Uppsala University and the Academic Hospital in Uppsala. The study will be conducted together with Karolinska Trial Alliance (KTA), which

Read more Read more

2017-09-04

NextCell Pharma AB to present at several events in next 2 weeks

NextCell Pharma AB (”NextCell”) informs that during the next two weeks there is ample opportunities for (potential) investors to attend presentations given by and conduct discussions with NextCell Pharma personnel. Sessions where NextCell Pharma representatives will be present: · Aktiespararna Södertälje – September 4th 18:30-21:00 · Advanced Medicinal Therapy Products – A game changer in medicine? – Malmoe, September 12th 13:00-17:00 · Nordic Life Science days, Malmoe – September 12th – 14th · Aktiespararna Burlöv – September 13th 19:00-21:00 During these meetings

Read more Read more

2017-08-10

NextCell Pharmas first delivery of ProTrans™

NextCell Pharma AB (”NextCell”) today, received the first delivery of the drug candidate ProTrans™ from their manufacturer PBKM.

NextCell Pharma AB (”NextCell”) today, received the first delivery of the drug candidate ProTrans™ from their manufacturer PBKM....

Read more Read more

2017-08-08

Stem cell company NextCell Pharma receives approval from Ethics Committee

NextCell Pharma AB (NEXTCL) announced today that approval has been obtained from the Ethics Testing Board EPN, to develop assays from umbilical cord tissue. The collection is performed by regular staff at the clinic at Karolinska University Hospital in Huddinge. The project is conducted by Edvard Smith, Professor of Molecular Genetics at the Department of Laboratory Medicine at Karolinska Institutet, and one of the founders of the Company. The results may be included in the Company's proprietary intellectual property regarding ProTrans. ProTrans is developed for stem cell therapies for

Read more Read more